Background Cholinesterase inhibitors, such as for example galantamine, donepezil and rivastigmine are approved for symptomatic treatment of Alzheimer’s Disease (Advertisement) in Canada. cost savings approximated at between $323 and $4,246. Bottom line Although there is normally uncertainty in approximated results, the very best information available shows that the initial choice for treatment of Advertisement ought… Continue reading Background Cholinesterase inhibitors, such as for example galantamine, donepezil and rivastigmine